Article info
Poster Presentations
Epidemiology, health services and outcome research
FRI0364 Real-World Incidence of Biologic Dose Escalation and Impact on Biologic Costs Among Patients with Rheumatoid Arthritis Treated with Intravenous Agents Abatacept, Infliximab or Tocilizumab
Citation
FRI0364 Real-World Incidence of Biologic Dose Escalation and Impact on Biologic Costs Among Patients with Rheumatoid Arthritis Treated with Intravenous Agents Abatacept, Infliximab or Tocilizumab
Publication history
- First published June 9, 2015.
Online issue publication
February 18, 2018
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© 2015, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions